Fact-checked by Grok 2 weeks ago

Kenneth Frazier


Kenneth C. Frazier (born December 17, 1954) is an American lawyer and pharmaceutical executive who served as president, chief executive officer, and chairman of the board of from 2011 to 2021, and as executive chairman until 2022, marking the first time an African American led a major pharmaceutical company as CEO. Raised in a challenging urban environment in , Frazier earned a B.A. with highest honors from in 1975 and a J.D. from in 1978 before joining Merck in 1992 as a legal executive. During his three-decade tenure at Merck, Frazier advanced from , where he managed high-stakes litigation including defenses against Vioxx-related claims, to top roles that emphasized expanded research investments, innovative medicine and vaccine development, and philanthropic efforts aligned with the company's long-standing humanitarian commitments. His executive stewardship delivered value to shareholders while prioritizing patient access and scientific progress, earning recognition for principled decision-making amid industry pressures on drug pricing and . Frazier's prominence extended beyond corporate strategy in when he became the first CEO to resign from President Donald Trump's American Manufacturing Council, stating that the move reflected a to oppose and following the Charlottesville rally—a decision that drew both praise for moral clarity and criticism for political signaling amid debates over the events' causal dynamics. As a former trustee of , he also directed the internal probe into the child abuse scandal, navigating institutional accountability under intense scrutiny. Post-retirement from Merck, Frazier has continued influencing governance through board service at institutions like and the Harvard Corporation, alongside advisory roles in legal reform.

Early life and education

Childhood in Philadelphia

Kenneth Frazier was born on December 17, 1954, in , , to Otis Frazier, a , and Clara Frazier, a homemaker. The second of three children, he grew up in the economically disadvantaged neighborhood of , characterized by poverty and urban challenges during an era of school desegregation efforts. His family background included a grandfather who had been a sharecropper, underscoring generations of limited economic opportunity. Frazier's mother died when he was twelve years old, leaving his father as the primary parental figure who instilled values of and achievement. His parents emphasized as a pathway out of hardship, with his father particularly motivating the children toward success despite the surrounding environment of inner-city struggles. Early exposure to racial tensions, including desegregation-related conflicts in local schools, contributed to Frazier's formative experiences in a tough neighborhood not far from . These circumstances fostered a personal emphasis on merit-based opportunity and individual effort, as reflected in Frazier's later recollections of his father's strong views on personal responsibility amid limited external support. emerged as one of his early heroes, symbolizing legal advocacy and advancement through excellence.

Academic and early professional influences

Frazier grew up in , attending local public schools in a challenging urban environment where his father worked as a and his mother passed away when he was 12. He graduated from high school at age 16 and enrolled at , earning a B.A. in in 1975 with highest honors. Frazier then attended , receiving his J.D. in 1978. His decision to pursue law stemmed from an early admiration for , the first Black U.S. justice, whom Frazier idolized for leveraging legal advocacy to drive through rigorous argumentation and evidence. This influence, rooted in the civil rights era, emphasized the law's potential to rectify injustices via factual persuasion rather than abstract ideals, shaping Frazier's commitment to empirical scrutiny in legal practice. At , Frazier benefited from mentors and professors who reinforced a disciplined, analytical approach to , prioritizing and verifiable evidence over ideological preconceptions. Following graduation, his initial professional steps at the firm Drinker Biddle & Reath as a summer exposed him to litigation's demands for precise, fact-driven advocacy, including early efforts focused on defending the through exhaustive review of empirical records, which later contributed to exonerations. These experiences honed his preference for causal analysis grounded in data, influencing his trajectory toward high-stakes legal roles.

Legal career

Work at Drinker Biddle & Reath

Frazier joined the Philadelphia-based Drinker Biddle & Reath as a litigation associate in 1978, shortly after earning his J.D. from . His early practice emphasized corporate litigation, where he developed expertise in defending clients against complex disputes, including those involving and pharmaceutical interests. During his tenure, Frazier handled representations for major corporate entities, honing skills in rigorous evidentiary analysis and strategic advocacy that prioritized factual substantiation over narrative appeals. This approach contributed to his growing reputation as a methodical litigator capable of navigating high-stakes defenses in competitive legal environments. By 1985, he had advanced to , becoming only the second African American to achieve that status at the firm, underscoring a merit-driven trajectory amid a traditionally selective process. Frazier's work at the firm spanned over a decade, during which he balanced demanding caseloads with professional development, establishing a foundation in corporate counsel that emphasized precision and accountability. His progression from to reflected consistent performance in a field where advancement hinged on demonstrable results rather than tenure alone.

Notable legal cases and advocacy

During his tenure at Drinker Biddle & Reath from 1978 to 1992, Frazier undertook significant litigation, particularly in capital cases, prioritizing forensic and evidentiary analysis to challenge convictions lacking causal substantiation. One landmark effort involved representing James Willie "Bo" Cochran, convicted in 1977 of murdering a white man in , and sentenced to death. Frazier, volunteering through the , led a team that uncovered and evidentiary flaws, including unreliable witness testimony and suppressed exculpatory material, leading to Cochran's release after 19 years and 4 months in 1997; a retrial that year resulted in based on reexamined ballistic and forensic data inconsistent with the original narrative. This case exemplified Frazier's approach to advocacy, rooted in rigorous scrutiny of physical evidence and procedural irregularities rather than appeals to broader social narratives, aligning with his selection of Drinker Biddle for its pro bono emphasis on leveling evidentiary disparities in high-stakes proceedings. He described initial impressions of Cochran's case as compelling due to discrepancies in the trial record, driving a focus on verifiable causal chains—such as timeline inconsistencies and forensic mismatches—over unsubstantiated claims. Such work contributed to broader patterns in Philadelphia's legal community during the 1980s, where pro bono efforts exposed systemic errors in convictions through DNA and ballistic retesting, though Frazier's involvement predated widespread DNA adoption and relied on traditional empirical methods. Frazier's legal practice underscored a commitment to due process via fact-based defenses, avoiding politicized strategies that subordinated evidence to ideology; this evidentiary discipline later informed his corporate risk assessments at Merck, where analogous causal reasoning evaluated litigation outcomes and innovation liabilities. His pro bono record, including participation in death penalty programs, highlighted the firm's role in approximately a dozen such interventions by the late 1980s, yielding exonerations grounded in irrefutable data rather than equitable pleas.

Tenure at Merck & Co.

Ascension to executive roles

Frazier joined in 1992 as , , and secretary of the Astra Merck group, a between Merck and focused on gastrointestinal pharmaceuticals. In this initial role, he managed legal matters including and protections during a period of consolidation and challenges from generic competitors. By 1994, he advanced to of public affairs, overseeing advocacy on policy issues affecting and . In January 1999, Frazier was promoted to and deputy , followed by and in December 1999, where he directed Merck's legal department, public affairs, and the Merck Company Foundation. His tenure as intensified with the Vioxx litigation, stemming from the 2004 withdrawal of the painkiller due to cardiovascular risks; Frazier led the defense against over 27,000 claims and more than 5,000 lawsuits, culminating in a $4.85 billion settlement in November 2007 that resolved the majority of cases without admitting liability. This effort preserved Merck's amid potential multibillion-dollar exposures, demonstrating rigorous application of evidentiary standards to limit damages. Frazier's ascent continued in November 2006 with promotion to executive vice president and , expanding his oversight to integrate legal strategy with business operations. In 2007, he assumed the role of executive vice president and of Global Human Health, directing , R&D pipeline protection, and international market strategies that supported revenue from key products like statins and vaccines. These positions underscored his contributions to safeguarding , which correlated with sustained innovation output and global sales growth exceeding $40 billion annually by the late 2000s, as robust deterred infringement and extended exclusivity periods.

CEO leadership (2011–2021)

Kenneth C. Frazier assumed the role of chief executive officer of Merck & Co. on January 1, 2011, following his election by the board on November 30, 2010, and his prior positions as president since May 2010 and executive vice president. His appointment marked him as the first African American CEO of a major pharmaceutical company, achieved through a progression from general counsel roles dating back to 1992, emphasizing legal expertise in patent litigation and corporate governance rather than diversity mandates. Under his leadership, Merck maintained annual revenues near $48 billion, with 2011 sales at $48.0 billion rising modestly to $48.7 billion by 2021, amid challenges from generic competition but offset by targeted growth in high-value segments. Frazier directed a strategic pivot toward and , exemplified by the 2014 U.S. FDA approval and launch of Keytruda () on September 4 for advanced , which expanded to multiple indications and generated $17.2 billion in 2021 sales, contributing over 35% of Merck's pharmaceutical revenue that year through robust successes and label expansions. This shift countered revenue erosion from patent expirations, such as Singulair's in 2012, which contributed to a temporary sales plateau, by prioritizing pipeline assets with potential over legacy products facing generic entry. To sustain amid these cliffs, Frazier championed elevated R&D expenditures, increasing investments to over $5 billion annually by the late 2010s and committing an additional $9 billion in the years following, focused on early-stage research in immuno- and biologics to underpin long-term revenue through novel therapies rather than cost-cutting alone. supported this approach, including the $11.5 billion acquisition of announced on September 30, 2021, to acquire sotatercept for pulmonary arterial hypertension and enhance synergies with Keytruda, closing in November 2021 as a capstone to his tenure's emphasis on external pipeline augmentation.

Key business decisions and outcomes

Under Frazier's leadership, Merck prioritized the commercialization of (Keytruda), an anti-PD-1 approved by the FDA in 2014 for advanced . The drug rapidly expanded into multiple indications, including non-small cell , driving substantial revenue growth; global sales reached $14.4 billion in 2020, a 30% increase from the prior year, accounting for nearly 30% of Merck's total $48 billion in sales. This focus contributed to Merck's exceeding $220 billion by mid-2019, with stock gains of approximately 40% in the preceding year, outperforming broader pharmaceutical peers amid expirations on legacy products. To address post-merger inefficiencies and impending revenue cliffs from drugs like Zocor and Fosamax, Frazier initiated a major restructuring in October 2013, announcing 8,500 job cuts—about 13% of the workforce—primarily in sales, administrative, and New Jersey-based operations, targeting $2.5 billion in annual cost savings by 2015. This built on prior reductions, culminating in over 36,000 positions eliminated across five years, enabling reallocation of resources to high-growth areas like and . The efficiency measures supported sustained R&D investment, with Merck's stock delivering compounded annual returns of roughly 10-12% from 2011 to 2021, surpassing the Health Care Index in periods of Keytruda acceleration despite industry headwinds. Merck pursued geographic diversification through partnerships in emerging markets, emphasizing cohabitation-style alliances over outright acquisitions to mitigate risks while accessing growth in , Latin America, and Africa. This strategy aligned with a four-part value-creation focusing on innovative products and productivity, yielding incremental sales from vaccines and therapeutics in high-potential regions. In response to the , Merck invested in two non-mRNA vaccine candidates, V590 ( vector) and V591 (vesicular stomatitis virus vector), via collaborations including with IAVI and Bioscience. However, Phase 1 data revealed inferior compared to mRNA platforms like Pfizer-BioNTech's, prompting discontinuation on , 2021, to redirect efforts toward antiviral treatments like . This evidence-based pivot preserved capital, avoiding escalation on low-efficacy assets amid competitive mRNA dominance. Frazier advocated for innovation-justified pricing to sustain R&D funding, arguing that high costs of drug development—averaging billions per approval—necessitated list prices reflecting value over international referencing or caps, which he warned could stifle U.S.-led breakthroughs. Despite rebates averaging 50% off U.S. list prices, this stance maintained margins, funding pipeline expansion while countering populist reforms. Overall, these decisions shifted Merck from defensive cost management to oncology-led growth, elevating enterprise value through empirical revenue multipliers from Keytruda exceeding restructuring savings.

Public stances and engagements

Resignation from Trump's Manufacturing Council

Kenneth Frazier was appointed to President 's American Council in early 2017, shortly after Trump's , as part of an advisory group aimed at strengthening U.S. policy. During his tenure, Frazier participated in council discussions on initiatives, contributing perspectives from the pharmaceutical sector. On August 14, 2017, following the violent clashes at the in , over the weekend of August 11-12, Frazier became the first CEO to resign from the council. In his statement, he cited "a responsibility to take a stand against and ," emphasizing that leaders must reject hatred, bigotry, and regardless of source. President responded via later that day, stating, "Now that Ken Frazier of Merck Pharma has resigned from President's Manufacturing Council, he will have more time to LOWER RIPOFF DRUG PRICES!" Frazier's prompted a wave of exits from the council, including those from CEO and CEO on the same day, followed by others such as and Campbell Soup executives, ultimately leading to disband the group on August 16. Merck experienced no discernible operational disruptions from the resignation, with shares rising approximately 0.6% that afternoon to close at $62.75. Investors largely viewed Frazier's decision positively, with minimal market volatility reported.

Positions on racial and corporate

Following the on May 25, 2020, Frazier publicly acknowledged systemic racism as a barrier requiring corporate intervention beyond statements or , emphasizing structural changes in hiring and access. He co-founded the OneTen coalition in June 2020, uniting over 120 companies to place 1 million Black Americans without four-year degrees into family-sustaining jobs by 2030 through skills-based hiring and career advancement pathways, prioritizing practical competencies over credentials to bridge gaps rooted in unequal systems. This approach focused on via workforce development rather than redistributive measures like . In a 2018 Harvard Business Review interview, Frazier articulated that corporations fulfill social responsibilities by generating value through and long-term investments, such as Merck's $10 billion-plus annual R&D spending, which funds therapies like Keytruda despite high prices (around $150,000 per year) necessary to sustain a pipeline where over 90% of projects fail. He argued this model—where pricing recoups development costs spanning 12-15 years—ultimately benefits society by advancing medical knowledge and reducing overall healthcare burdens, rejecting short-term or wealth transfers in favor of causal linkages between commercial success and gains. Frazier consistently advocated merit-based evaluation in talent development, describing effective diversity efforts as those that identify and measure "hidden talent" fairly without compromising , drawing from his own rise through and skill-building amid opportunity disparities. He cautioned that overemphasizing historical inequities risks undervaluing individual , urging businesses to foster environments where drives advancement, as evidenced by his personal oversight of Merck's metrics tied to incentives while maintaining rigorous hiring standards.

Controversies and criticisms

Backlash over political activism

Frazier's resignation from President 's American Manufacturing Council on August 14, 2017, following Trump's response to the Charlottesville violence, drew immediate criticism from Trump, who tweeted that Frazier would now have "more time to LOWER RIPOFF DRUG PRICES!" This response highlighted conservative accusations that Frazier prioritized symbolic gestures over substantive policy engagement, as the council's manufacturing advice had reportedly been sidelined by the administration prior to his exit. Analysts from right-leaning perspectives argued that such risked alienating stakeholders without advancing interests, potentially forfeiting opportunities for regulatory on . Frazier's later leadership in corporate opposition to state voting restrictions, including co-organizing a 2021 statement signed by over 700 executives urging protection of voting access, elicited backlash from Republican figures and conservative media as an overreach of corporate influence into partisan politics. Outlets like the New York Post labeled it a "woke" bid to dictate election laws, contrasting with Frazier's defenses of free-market principles and suggesting it aligned with left-leaning agendas rather than neutral corporate responsibility. Critics contended this form of activism constituted virtue signaling that could distract from core operations, though Merck's stock performance under Frazier—doubling in value—showed no immediate empirical detriment to shareholder returns. Internally at Merck, Frazier acknowledged potential employee disagreements with his stances, addressing at a plant post-resignation by emphasizing his role was not to dictate political beliefs. While no documented declines emerged, analyses debated opportunity costs, positing that high-profile might dilute focus on and regulatory amid polarized climates. Conservative commentators viewed these actions as emblematic of broader CEO trends conflating with , potentially eroding bipartisan essential for policy wins.

Debates on pharmaceutical pricing and innovation

During Kenneth Frazier's tenure as CEO of Merck & Co., the company's blockbuster immunotherapy drug Keytruda (pembrolizumab) faced scrutiny for its high list price, exceeding $150,000 annually, which critics argued exacerbated access barriers despite the drug's efficacy in treating various cancers. Frazier defended such pricing as essential to recover substantial research and development (R&D) investments, noting that developing innovative therapies like Keytruda required billions in upfront costs amid high failure rates in clinical trials, with Merck's annual R&D expenditures reaching approximately $8 billion by the early 2010s and sustaining high levels through oncology-focused initiatives. He emphasized that elevated U.S. prices reflected the value delivered, such as improved survival rates—for instance, Keytruda's approval for multiple indications demonstrated median overall survival extensions of several months to years in advanced melanoma and non-small cell lung cancer trials—arguing that without recouping these costs, future innovation would diminish. The debate intensified in when President , responding to Frazier's from the American Manufacturing Council, tweeted that Frazier would now have "more time to LOWER RIPOFF DRUG PRICES," highlighting U.S. consumers' disproportionate burden compared to lower prices abroad due to foreign . This critique aligned with economic analyses showing that the U.S. effectively subsidizes global pharmaceutical innovation, as other nations' negotiated caps transfer R&D risk to American payers without equivalent contributions to new . Frazier countered by advocating for market-driven pricing tied to therapeutic outcomes rather than arbitrary reductions, warning that aggressive interventions could undermine the incentives for high-risk R&D investments that yield breakthroughs like checkpoint inhibitors. Proposals for price caps, often advanced by left-leaning policymakers and echoed in media narratives prioritizing immediate access over long-term incentives, have been challenged by indicating that such controls reduce . Studies across countries demonstrate that price regulations correlate with fewer new drug approvals and lower R&D investment, with one analysis estimating that a 10% reduction in expected U.S. revenues could decrease by up to 15%, as firms redirect resources from high-uncertainty projects. Frazier's stance reflected this causal dynamic, prioritizing sustained R&D funding—Merck's pipeline under his leadership generated multiple approvals—as critical to addressing unmet medical needs, rather than short-term affordability measures that risk stifling the very advancements enabling value-based care.

Post-Merck activities

Executive Chairman role and transitions

Kenneth C. Frazier retired as and of Merck & Co. on June 30, 2021, after a decade in the , transitioning to chairman of the board effective July 1, 2021, to facilitate a smooth handover to successor Robert M. Davis. In this capacity, Frazier provided strategic oversight and guidance during the leadership change, ensuring alignment with Merck's established priorities in , particularly in and , without reported disruptions to ongoing operations or pipeline initiatives. Davis, an internal promotee who had served as since 2014, assumed the CEO position with a mandate to maintain the company's focus on innovation-driven growth, reflecting continuity in Merck's core business model amid the executive shift. Frazier's tenure as executive chairman extended through November 30, 2022, during which the board credited him with stabilizing governance and reinforcing long-term strategic direction, including sustained investments in products like Keytruda. No significant policy or operational pivots were attributed to the transition; instead, Merck reported steady revenue growth and R&D expenditure levels comparable to prior years, underscoring the absence of material leadership-induced volatility. Upon his full retirement from the board at the end of 2022, after nearly 30 years at the company, succeeded Frazier as chairman effective , 2022, further consolidating internal succession and preserving institutional knowledge. This phased wind-down exemplified deliberate board planning to mitigate risks associated with CEO turnover in a highly regulated industry.

Involvement in venture capital and advisory positions

Following his departure from Merck's executive leadership, Frazier assumed the role of Chairman of Health Assurance Initiatives at the firm General Catalyst on July 21, 2021, focusing on leveraging private capital to develop scalable solutions addressing systemic health challenges, including through strategic investments in and partnerships. In this capacity, he guides the firm's approach to deploying capital toward innovations that enhance health outcomes beyond traditional pharmaceutical models, emphasizing empirical approaches to unmet needs in areas like chronic management and preventive care. Frazier extended his advisory influence into healthcare services by accepting the chairmanship of the board of directors at Transcarent in February 2023, a platform specializing in employer-sponsored healthcare navigation to reduce costs and improve access via data-driven interventions. His prior service on the board of directors, spanning 2009 to 2022—including as lead from approximately 2018 onward—provided oversight on sector amid transitions to lower-carbon strategies, ending with his announced retirement ahead of the 2022 annual shareholder meeting. In public engagements, Frazier addressed policy intersections of and in a November 2022 STAT News interview, asserting that threats to democratic institutions—such as diminished rational discourse—undermine the evidence-based foundations of pharmaceutical advancement and regulatory stability. He reinforced themes of principled, data-informed decision-making in commencement addresses, including at in May 2023, where he spoke to over 800 graduates on leadership amid societal challenges, and at in May 2025 for the Class of 2025.

Recognition and legacy

Awards and honors

Frazier was elected a fellow of the American Academy of Arts and Sciences in 2012, recognizing his leadership in the during Merck's development and commercialization of Keytruda (), an that achieved peak annual sales exceeding $25 billion by 2023 under his stewardship. In 2023, he received the Bower Award for Business Leadership from The Franklin Institute, which honors executives who exemplify innovative management and scientific advancement in U.S. business; the award cited Frazier's role in driving Merck's revenue growth from $40 billion in 2010 to over $60 billion by 2021, largely through Keytruda's expansion into multiple cancer indications following successful clinical trials and regulatory approvals. Frazier was presented the John Minor Wisdom Award by the in May 2025, an honor for distinguished contributions to the , reflecting his earlier tenure as Merck's where he led the defense against thousands of Vioxx-related claims, settling major litigation for $4.85 billion in 2007 while preserving the company's viability. Additional recognitions include the Forbes Lifetime Achievement Award for Healthcare in 2019 for sustained innovation in and access, and the Deming Cup for Operational Excellence from in 2021, awarded for Merck's supply chain efficiencies and R&D productivity gains during his CEO tenure.

Impact on business and industry

Under Frazier's leadership as CEO of Merck from January 2011 to June 2021, the company accelerated its recovery from the long-term repercussions of the 2004 Vioxx withdrawal, which had involved multibillion-dollar settlements and litigation, by prioritizing innovation and operational refocus. Key to this was the 2014 FDA approval and subsequent rapid commercialization of Keytruda (), an anti-PD-1 that generated $4.2 billion in 2019 sales alone and eclipsed competitors in multiple cancer indications, establishing Merck as a dominant force in immuno-oncology. This shift contributed to Merck's stock price rising approximately 150% during his tenure, with expanding from about $120 billion in early 2011 to over $230 billion by late 2020, reflecting investor confidence in sustained R&D —Merck's annual spending increased to around $10 billion by 2019—and pipeline prioritization over diversification into consumer health. Frazier's approach influenced broader dynamics by exemplifying CEO-level advocacy for evidence-based defenses of amid scrutiny, countering narratives of excess profits with on R&D costs and value creation. In speeches and congressional testimonies, he rebutted proposals for international reference and rebate-focused reforms, arguing they would stifle in high-risk , as evidenced by his 2019 BIO remarks emphasizing capitalism's role in advancing therapies like Keytruda that extended patient survival rates in trials by months to years. This candor challenged activist pressures for immediate price concessions, promoting instead a framework where reflects causal links between and clinical outcomes, such as Keytruda's to over 30 indications by 2021. Critiques of Frazier's impact highlight uneven results in diversity initiatives despite his public emphasis on racial , with Merck's C-suite remaining predominantly non-diverse upon his departure—mirroring industry-wide stagnation where Black CEOs comprised under 1% of leaders. Empirical data on DEI programs under his advocacy showed limited causal uplift in executive representation, as broader sector metrics post-2011 reveal persistent underrepresentation tied more to gaps than resolved systemic barriers. Frazier's own trajectory—from handling Vioxx litigation to CEO—empirically validates meritocratic advancement through performance in high-stakes legal and strategic roles, rather than dependency on equity-focused interventions, aligning with outcomes where individual outperformed collective remedial efforts in corporate ascent.

References

  1. [1]
    Kenneth C. Frazier's Biography - The HistoryMakers
    Pharmaceutical executive, lawyer, and corporate general counsel Kenneth C. Frazier was born on December 17, 1954 in Philadelphia, Pennsylvania.
  2. [2]
    Robert M. Davis to Succeed Kenneth C. Frazier as Chairman of Merck
    Oct 26, 2022 · Kenneth C. Frazier has served as executive chairman of Merck's board of directors since July 2021, following his retirement from a decade-long ...
  3. [3]
    Kenneth C. Frazier - The Conference Board
    Kenneth C. Frazier is the Executive Chairman of Merck's board of directors, a role he began in July 2021, following his retirement from a decade-long tenure ...Missing: facts | Show results with:facts
  4. [4]
    What You Should Know About Ken Frazier, The CEO Who Just Quit ...
    Aug 14, 2017 · Frazier was made Merck's corporate counsel – a company's chief lawyer – in 1999. His biggest task was defending Merck from an onslaught of ...<|separator|>
  5. [5]
    Kenneth Frazier Joins Harvard Corporation
    Feb 12, 2024 · Harvard University has announced that Kenneth C. Frazier will join the Harvard Corporation. The Corporation, also known as the President and Fellows of Harvard ...Missing: education | Show results with:education
  6. [6]
    [PDF] Frazier, Kenneth C., 1954 - The HistoryMakers
    May 30, 2023 · Frazier was born on December 17, 1954 in philadelphia, pennsylvania to janitor and former sharecropper otis Tindley Frazier and homemaker Clara ...Missing: early poverty
  7. [7]
    Kenneth Frazier: Former CEO of Merck & Co.
    Growing Up. Frazier was born and raised in North Philadelphia during a time of school desegregation. His father Otis was a janitor at a United Parcel Service ...Missing: childhood background
  8. [8]
    Kenneth C. Frazier | The Franklin Institute
    He retired as Merck's president and CEO in 2021, and stepped down as executive chairman in 2022, but Frazier's dedication to service has hardly diminished.
  9. [9]
    How Ken Frazier's career prepared him to 'stand against intolerance'
    Aug 15, 2017 · Frazier's grandfather was born into slavery, his mother passed away when he was 12 and his father worked as a janitor in North Philadelphia. His ...Missing: childhood family
  10. [10]
    From the son of a janitor to CEO of Merck: Meet Kenneth Frazier ...
    Aug 15, 2017 · Frazier, who's 62, grew up in North Philadelphia. His father, who was a janitor, motivated his kids to be successful. "My father had a very ...<|separator|>
  11. [11]
    A national championship winning basketball coach joins two ...
    Apr 22, 2022 · Frazier often refers to the influence on his life of growing up in a modest home in North Philadelphia near Temple's Main Campus. His father, a ...Missing: reliance | Show results with:reliance
  12. [12]
    A Dose of Optimism - Harvard Law School
    Jul 1, 2011 · The new CEO of pharmaceutical giant Merck, Kenneth Frazier '78 is driven by high hopes for the company and what it can do.
  13. [13]
    [PDF] On Leadership - Association of Corporate Counsel
    Please tell us about some of your early influences. Ken Frazier: Like a lot of people, my earliest influences were my parents. I grew up in the inner ...Missing: self- reliance<|control11|><|separator|>
  14. [14]
    Kenneth C. Frazier (1954- ) | BlackPast.org
    Mar 21, 2014 · Kenneth Frazier was born in Philadelphia, Pennsylvania to Otis and Clara Frazier on December 17, 1954. Along with his three siblings, Frazier ...Missing: childhood family background
  15. [15]
    Kenneth Frazier - Wikipedia
    He is executive chairman and former CEO of the pharmaceutical company Merck & Co. (known as MSD outside of North America). After joining Merck & Co. as general ...Early life and education · Career · Merck & Co. · Other work
  16. [16]
    [PDF] Kenneth C. Frazier '75 - Penn State Alumni Association
    Frazier graduated from Penn State in 1975 with a B.A. in political science and earned his J.D. from Harvard Law. School in 1978. He regards his education as a ...
  17. [17]
    Merck C.E.O. Ken Frazier on Death Row Cases and the Corporate ...
    Mar 9, 2018 · What drew you to the study of law? I've always admired lawyers who use their power to affect social change, and Thurgood Marshall was always a ...
  18. [18]
    Merck Has A Great Future, Because It Has A Soul: Ken Frazier
    Feb 4, 2020 · In this uplifting and fascinating conversation, Ken Frazier, the highly successful CEO of pharmaceutical giant Merck, talks about a company ...Missing: influence reliance
  19. [19]
    Merck's Risky Bet on Research - Bloomberg.com
    Apr 21, 2011 · After graduating from high school at 16, Frazier attended Pennsylvania State University. He told friends he would be a lawyer, inspired by civil ...<|separator|>
  20. [20]
    Powered by Principle - Kenneth Frazier's Path to Success
    Sep 1, 2017 · Embrace your passion – Kenneth Frazier was drawn to the legal profession by his admiration for Judge Thurgood. He was drawn to the courtroom ...
  21. [21]
    Kenneth C. Frazier, Winner of the ISO 10018 Honorary CEO Citation ...
    After graduating from Harvard Law School, he worked for a major law firm that handled the Merck account before eventually joining the pharmaceutical company's ...Missing: reliance | Show results with:reliance
  22. [22]
    ALI Oral History Series: Ken Frazier | The American Law Institute
    Kenneth Frazier: Well, I was born and raised in north Philadelphia, not very far from where we're sitting right now. A neighborhood that was a tough ...Missing: poverty | Show results with:poverty<|separator|>
  23. [23]
    Alumni Spotlight: Interview with Kenneth C. Frazier, Chairman ...
    Mar 29, 2013 · A: I joined Drinker Biddle as a litigation associate in 1978 and left the firm as a litigation partner in 1992. Q: What was your most memorable ...Missing: 1985 | Show results with:1985
  24. [24]
    Kenneth Frazier on His Unlikely Path to Merck CEO, the Current ...
    Nov 28, 2023 · Against all odds, the son of a janitor from North Philadelphia earned degrees from Penn State University and from Harvard Law School.Missing: reliance | Show results with:reliance
  25. [25]
    Kenneth C. Frazier - New Jersey Equal Justice Library and Archive
    Discover the legacy of Kenneth C. Frazier—CEO, civil rights advocate, and pro bono leader—whose legal and corporate work advanced equal justice for all.Missing: early exonerations
  26. [26]
    [PDF] Finding Aid to The HistoryMakers ® Video Oral History with Kenneth ...
    the law firm of Drinker Biddle and Reath LLP in Philadelphia, Pennsylvania. In. 1985, Frazier became the second African American partner at the firm. He left.
  27. [27]
    Merck CEO and Drinker Biddle Alumnus Ken Frazier Featured in ...
    Mar 12, 2018 · Ken talks about race, justice, doing pro bono working during his time at Drinker Biddle, and much more. https://www.faegredrinker.com ...Missing: 1985 | Show results with:1985
  28. [28]
    [PDF] Merck's Ken Frazier Volunteered and Saved a Life
    Apr 5, 2009 · Today, Frazier is Executive Vice President and President, Global Human Health, Merck & Co., Inc. Still head of EJI,. Bryan Stevenson also ...Missing: pro bono early exonerations
  29. [29]
    Success Stories - American Bar Association
    Jul 2, 2025 · In 1997, the Philadelphia office of Drinker Biddle & Reath along with Kenneth Frazier ... Uncovering that misconduct can be difficult for pro bono ...
  30. [30]
    Kenneth C. Frazier to Retire as Merck CEO; Board Elects Robert M ...
    Feb 4, 2021 · Frazier was promoted to vice president and deputy general counsel in January 1999. In December 1999, he became senior vice president and ...Missing: timeline | Show results with:timeline
  31. [31]
    Businesses Exist to Deliver Value to Society
    Kenneth Frazier's story is far from that of a typical CEO. He grew up in a tough inner-city neighborhood in Philadelphia. His education focused on a career ...Missing: biography | Show results with:biography
  32. [32]
    Kenneth Frazier to Retire as Merck CEO | The American Law Institute
    Feb 10, 2021 · In December 1999, he became senior vice president and general counsel. In November 2006, he was promoted to executive vice president and general ...Missing: timeline promotions
  33. [33]
    A timeline of Ken Frazier's tenure at Merck
    Oct 28, 2022 · Here's a timeline of notable moments during Frazier's three-decade career at the drugmaker ... 2007 Promoted to EVP/president of Merck's ...Missing: promotions | Show results with:promotions
  34. [34]
    Merck Board Elects Kenneth C. Frazier as Next CEO; Richard T ...
    Nov 30, 2010 · He received his bachelor's degree from The Pennsylvania State University and holds a J.D. from Harvard Law School. About Richard T. Clark.
  35. [35]
    Merck Announces Full-Year and Fourth-Quarter 2011 Financial ...
    Feb 2, 2012 · Full-year 2011 worldwide sales were $48.0 billion, an increase of 4 percent, which includes a 2 percent benefit from foreign exchange, compared to full-year ...
  36. [36]
    Merck (MRK) - Revenue - Companies Market Cap
    Annual revenue ; 2013, $44.03 B · -6.84% ; 2012, $47.26 B · -1.62% ; 2011, $48.04 B · 4.48% ; 2010, $45.98 B · 67.66%.
  37. [37]
    Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for ...
    Pembrolizumab a New Option for Metastatic Melanoma. On September 4, 2014, the US Food and Drug Administration (FDA) approved pembrolizumab (Keytruda; Merck ...<|separator|>
  38. [38]
    Merck Announces Fourth-Quarter and Full-Year 2021 Financial ...
    Feb 3, 2022 · Full-year 2021 pharmaceutical sales increased 17% to $42.8 billion. ... COVID-19-related disruptions negatively affected sales in 2021, but to a ...
  39. [39]
    [PDF] testimony of kenneth c. frazier, ceo - Senate Finance Committee
    Feb 26, 2019 · We have invested more than $5 billion in the last five years, and we plan to invest $9 billion more over the next few years to increase ...
  40. [40]
    Merck to Acquire Acceleron Pharma Inc.
    Sep 30, 2021 · The transaction is expected to close in the fourth quarter of 2021. Merck Investor Call. Investors, journalists and the general public may ...
  41. [41]
    CEO Kenneth C. Frazier: Merck's Strategy Of “Investing Thoughtfully ...
    May 6, 2019 · Merck's strategy of “investing thoughtfully” in science-based R&D is paying off, says CEO Kenneth C. Frazier. For the first quarter, ...
  42. [42]
    2021 CEO of the Year: Inside Ken Frazier's Long Game
    Oct 25, 2021 · The Pope may seem an outlier, but Frazier, who turns 67 in December, says they actually had a lot to talk about when they met in 2017. The ...
  43. [43]
    Merck's Strategy Past Keytruda Revealed at First Investor Day in Years
    Jun 20, 2019 · Merck's stock has jumped almost 40% in the past year, giving the company a market value of nearly $220 billion. The company's Keytruda sales ...
  44. [44]
    Merck to slash annual costs by $2.5 billion, cut 8,500 jobs | Reuters
    Oct 1, 2013 · But half the job cuts from Merck's new restructuring will come ... Merck Chief Executive Kenneth Frazier said in an interview. Frazier ...Missing: layoffs | Show results with:layoffs<|separator|>
  45. [45]
    Merck tallies 36000 job cuts in 5 years of restructuring - Fierce Pharma
    Aug 13, 2015 · The not-so-good news: Several thousand payroll reductions are yet to come. Merck CEO Kenneth Frazier ... restructuring Merck rolled out in 2013, ...
  46. [46]
    Merck Announces Fourth-Quarter and Full-Year 2020 Financial ...
    Feb 4, 2021 · Growth in oncology was largely driven by sales of KEYTRUDA, which were $4.0 billion for the quarter. Global sales growth of KEYTRUDA ...
  47. [47]
    Merck's Growth Strategy: Cohabitation over Marriage
    Apr 12, 2011 · Kenneth Frazier, Merck's CEO since January 1, is sticking to his strategy of expanding in emerging markets through partnerships, ...
  48. [48]
    Merck Executing on Strategy to Position Company for Long-Term ...
    Nov 10, 2011 · Merck intends to achieve long-term, sustainable growth by delivering on its four-part strategy for creating shareholder value.
  49. [49]
    Merck Takes 3 Major Shots at COVID-19: Themis, IAVI ... - BioSpace
    May 26, 2020 · Merck has largely stayed out of the COVID-19 battle, but exploded into it with three major deals and collaborations today.
  50. [50]
    Merck Discontinues Development of SARS-CoV-2/COVID-19 ...
    Jan 25, 2021 · The company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, and plans to focus its SARS-CoV-2/COVID-19 research ...Missing: Frazier | Show results with:Frazier
  51. [51]
    Merck chief Frazier's R&D-based drug price defense a tough sell for ...
    Nov 2, 2015 · Frazier's main talking points are that R&D is expensive, and that although prices on new drugs are expensive, the impact of brand competition ...
  52. [52]
    Merck CEO sees legal challenge if U.S. adopts drug pricing based ...
    Jun 21, 2019 · Merck & Co Chief Executive Ken Frazier said on Thursday a rule to base the price the U.S. government pays for some prescription drugs in it ...
  53. [53]
    Tale of 2 CEOs: Merck chief treads carefully on pricing, while Pfizer's ...
    Nov 2, 2018 · Across its U.S. portfolio, Merck is discounting its drugs by about 50% from list prices, Frazier said. That stat doesn't illustrate, however, ...
  54. [54]
    Merck CEO, Kenneth Frazier, leaves Trump manufacturing council
    ... appointment was announced in January, just days after President Trump took office. Frazier's Aug. 15 resignation from the Council, was for all intents and ...Missing: date | Show results with:date
  55. [55]
    Trump: CEOs leaving advisory council 'out of embarrassment'
    Aug 15, 2017 · Just after taking office, Trump announced the establishment of a manufacturing council, with Frazier as the only black male executive included.Missing: date | Show results with:date
  56. [56]
    The C.E.O. Who Stood Up to President Trump: Ken Frazier Speaks Out
    Feb 19, 2018 · Kenneth C. Frazier, the chief executive of the pharmaceuticals company Merck, served on one of Mr. Trump's business advisory councils in the early days of the ...
  57. [57]
    Merck CEO resigns from Trump's American Manufacturing Council
    Aug 14, 2017 · Merck CEO resigns from Trump's American Manufacturing Council, citing 'responsibility to take a stand against intolerance.'
  58. [58]
    Merck CEO quits Trump panel in 'stand against violence and ...
    Aug 14, 2017 · Kenneth Frazier said he would step down from one of Trump's advisory panels, citing "a responsibility to take a stand against violence and ...
  59. [59]
    CEOs Of Merck, Under Armour And Intel Resign From Trump's ...
    Aug 14, 2017 · In a statement on his resignation, Frazier said, "America's leaders must honor our fundamental values by clearly rejecting expressions of hatred ...
  60. [60]
    Donald J. Trump on X: "Now that Ken Frazier of Merck Pharma has ...
    Aug 14, 2017 · Now that Ken Frazier of Merck Pharma has resigned from President's Manufacturing Council,he will have more time to LOWER RIPOFF DRUG PRICES!
  61. [61]
    Trump attacks Merck CEO for quitting manufacturing council over ...
    Aug 14, 2017 · “I am resigning from the President's American Manufacturing Council,” Frazier said in a statement. “America's leaders must honor our ...
  62. [62]
    Here's who's in and out of Trump's economic advisory councils - CNBC
    Aug 16, 2017 · American Manufacturing Council ; Kenneth Frazier, Merck CEO, Aug 14, 2017 ; Alex Gorsky, Johnson & Johnson CEO, Aug. 16, 2017 ; Greg Hayes, United ...
  63. [63]
    Merck CEO quits Trump's industry council - CBS News
    Aug 14, 2017 · Merck (MRK) shares rose 37 cents, or 0.61 percent, trading at $62.75 a share Monday afternoon. President Donald Trump is being criticized for ...
  64. [64]
    Merck CEO Ken Frazier Resignation and Investor Reaction
    Aug 16, 2017 · Most investors respect Merck CEO Kenneth Frazier's decision to resign from US President Donald Trump's manufacturing council.
  65. [65]
    OneTen: Creating a New Pathway for Black Talent - Baker Library
    Aug 9, 2021 · OneTen aims to help 1 million Black Americans launch careers in the next 10 years by cultivating a comprehensive system that focuses on skills first.
  66. [66]
    [PDF] YEAR - ONE - OneTen
    Tackling racial disparities in employment requires the reimagination of how we hire, develop and promote talent. By prioritizing skills over degrees, companies ...
  67. [67]
    William Kolbe column: What is so un-American about DEI? - Yahoo
    Jul 14, 2025 · Former Merck CEO Ken Frazier said, “At its best, DEI is about developing talent, measuring it in a fair way and finding hidden talent and ...<|separator|>
  68. [68]
    Merck CEO Resigns From President's Manufacturing Council ...
    Aug 14, 2017 · Merck CEO Kenneth Frazier has resigned from the President's American Manufacturing Council, dismayed that Trump hasn't responded more forcefully to the weekend ...
  69. [69]
    When CEOs Play Politics, Shareholders Can Take Them to Court
    May 23, 2018 · Some might call Merck CEO Kenneth Frazier's decision to resign from the council brave, but his company would have gained a significant ...<|separator|>
  70. [70]
    When Should CEOs Take a Political Stand? - Yale Insights
    Aug 16, 2017 · On Monday, August 14, Merck CEO Kenneth Frazier resigned from Trump's American Manufacturing Council ... shareholders making it so hard to ...
  71. [71]
    Black CEOs urge companies to oppose restrictive voting laws - CNBC
    Mar 31, 2021 · Merck CEO Ken Frazier is helping lead an effort among Black business executives to push corporate America to be more vocal in favor of voting ...Missing: activism | Show results with:activism
  72. [72]
    Woke CEOs' foolhardy bid to shape voting laws - New York Post
    Apr 12, 2021 · ... woke executives ... Merck CEO Kenneth Frazier and former American Express CEO Kenneth ...
  73. [73]
    Companies defend voting rights as GOP lashes out against 'woke ...
    Companies defend voting rights as GOP lashes out against 'woke corporations' · More than 360 bills with restrictive voting provisions have been introduced in 47 ...
  74. [74]
    Ken Frazier: Listening with Respect | Duke's Fuqua School of Business
    As CEO of Merck, Ken Frazier didn't shy away from taking a position or making a statement that he knew some employees might disagree with.
  75. [75]
    [PDF] Assessing the Impact of CEO Activism - Harvard Business School
    Feb 14, 2019 · And Merck CEO Ken Frazier stepped down from one of President Trump's business advisory councils to protest what he viewed as an equivocal ...Missing: stock | Show results with:stock
  76. [76]
    Companies risk backlash from 'woke warriors' when they comment ...
    Apr 13, 2021 · Companies risk backlash from 'woke warriors' when they comment on political issues: former AmEx CEO ... Kenneth Frazier, CEO of Merck, as well as ...
  77. [77]
    High-priced cancer drugs are driving pharma revenue - Lown Institute
    Nov 1, 2021 · When Merck set the price for its immunotherapy cancer drug Keytruda at more than $150,000 per year, doctors and patients were alarmed.
  78. [78]
    Trends in prices of checkpoint inhibitors in the US, 2016-2023.
    May 29, 2024 · In 2023, monthly prices for the 6 drugs ranged from $11,961 (durvalumab) to $15,043 (pembrolizumab). From 2016-2023, inflation-adjusted prices ...
  79. [79]
    Merck chief defends $8B R&D budget as vital long-term investment
    Dec 14, 2011 · And Merck CEO Kenneth Frazier is mounting a strong defense for his $8 billion R&D budget. In a clear jab at Pfizer, which has outperformed Merck ...
  80. [80]
    Why Merck's CEO Needn't Worry About Trump's Drug Pricing Tweet
    Aug 14, 2017 · Trump responded that Frazier would now have “more time to lower ripoff drug prices!” Now that Ken Frazier of Merck Pharma has resigned from ...<|separator|>
  81. [81]
    7 things to know about the pharma CEO who incurred Trump's wrath
    the maximum contribution — to former President Obama's reelection campaign in 2012. He does not appear to have ...Missing: achievements controversies
  82. [82]
    [PDF] The Evidence Base on the Impact of Price Controls on Medical ...
    Sep 14, 2021 · This issue brief reviews the evidence on the impact of price controls on biopharmaceutical innovation and calibrates what this evidence implies ...
  83. [83]
    The Hidden Toll of Drug Price Controls: Fewer New Treatments and ...
    Jul 17, 2023 · 29 A more recent study of 19 OECD countries finds that five out of six broad categories of pharmaceutical price controls reduced revenues.
  84. [84]
    Analysis Finds Meaningful Impact on Pharmaceutical Innovation ...
    Feb 18, 2025 · For every 10% reduction in expected U.S. revenues, pharmaceutical innovation is expected to decline by up to 15%, finds a new Schaeffer ...
  85. [85]
    From BIO meeting, Merck CEO backs capitalism, rebuts industry's ...
    Jun 5, 2019 · Frazier made no apology for being in a profit-seeking business, defending capitalism as a driving force behind the drugs available today. “Our ...
  86. [86]
    The price of innovation - the role of drug pricing in financing ...
    Mar 20, 2019 · This manuscript presents a conceptual framework to better understand the role played by drug prices to influence the ability of pharmaceutical firms to raise ...
  87. [87]
    Kenneth C. Frazier Joins General Catalyst As Chairman Of Its Health ...
    Jul 21, 2021 · Kenneth C. Frazier, Merck Executive Chairman and former CEO, will be joining General Catalyst in the newly created role of Chairman, Health Assurance ...
  88. [88]
    Ken Frazier Joins Investment Firm to Focus on Health Assurance ...
    Jul 22, 2021 · Kenneth Frazier has stepped down from his post at the pharmaceutical company to join venture capital firm General Catalyst as its newest chairman of health ...
  89. [89]
    Ken Frazier - UCLA Anderson School of Management
    Kenneth C. Frazier is the Executive Chairman of Merck's board of directors, a role he began in July 2021, following his retirement from a decade-long tenure as ...Missing: facts | Show results with:facts
  90. [90]
    Ken Frazier to Chair Transcarent Board of Directors
    Feb 21, 2023 · Industry leader Ken Frazier has been appointed to chair the company's board of directors. This addition to the Board is a formative milestone for Transcarent.
  91. [91]
    ExxonMobil lead director Ken Frazier to retire; Jay Hooley to ...
    Mar 22, 2022 · Lead independent director Kenneth C. Frazier has announced his intention not to stand for re-election to the board at the annual meeting of shareholders.
  92. [92]
    ExxonMobil Lead Director Ken Frazier to Retire; Jay Hooley to ...
    Mar 22, 2022 · Lead independent director Kenneth C. Frazier has announced his intention not to stand for re-election to the board at the annual meeting of shareholders.
  93. [93]
    Former Merck CEO: Democracy, the drug industry are in danger
    he's disappointed it didn't succeed — and on ...Missing: impact | Show results with:impact
  94. [94]
    Bowie State University Announces Spring Commencement Speaker
    Mar 8, 2023 · – Kenneth C. Frazier, executive chairman of Merck & Co., Inc. board of directors, will deliver remarks to over 800 graduates at Bowie ...Missing: addresses | Show results with:addresses
  95. [95]
    Kenneth C. Frazier, Chairman of General Catalyst's Health ...
    Apr 28, 2025 · Prior to joining Merck, Frazier was a partner with the Philadelphia law firm of Drinker Biddle & Reath. Upon his retirement from Merck, Frazier ...
  96. [96]
    Kenneth C. Frazier | American Academy of Arts and Sciences
    Kenneth C. Frazier, a Fellow of the American Academy since 2012, is the Chairman and CEO of Merck & Co, Inc.
  97. [97]
    Merck Announces Fourth-Quarter and Full-Year 2023 Financial ...
    Feb 1, 2024 · KEYTRUDA Sales Grew 19% to $25.0 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 21% · GARDASIL/GARDASIL 9 Sales Grew 29% to $8.9 ...
  98. [98]
    Kenneth C. Frazier Receives John Minor Wisdom Award
    May 20, 2025 · Prior to joining Merck in 1992, Frazier was a Partner with Drinker Biddle & Reath (now Faegre Drinker Biddle & Reath). Upon retiring from ...
  99. [99]
    Merck Provides Update on Strategic Actions to Transform the ...
    Jan 12, 2015 · In 2014, Merck engaged in multiple research collaborations in oncology, and data for KEYTRUDA was presented in seven different types of cancer.
  100. [100]
    Merck's Frazier to remain CEO beyond 2019 - CNBC
    Sep 26, 2018 · Under Frazier, Merck has also seen its cancer immunotherapy Keytruda rake in blockbuster sales and become one of the leading products in a ...<|separator|>
  101. [101]
    Merck CEO Kenneth Frazier to retire at the end of June
    Feb 4, 2021 · Under Frazier's leadership, Keytruda has eclipsed Bristol Myers Squibb's cancer immunotherapies, which hit the market first. Keytruda's sales ...Missing: transformation oncology
  102. [102]
    https://business.columbia.edu/leadership-and-ethics-news/bernstein-center-leadership-and-ethics/leading-long-term-how-kenneth
  103. [103]
    Leading For The Long-Term: How Kenneth Frazier Fulfills Merck's ...
    Jan 17, 2019 · Under Mr. Frazier's leadership, Merck substantially increased investment in research and refocused the organization on the launch and growth ...
  104. [104]
    Ken Frazier - CNBC
    Oct 3, 2023 · Ken substantially increased Merck's investment in research, including early research, while refocusing the organization on the launch and growth ...Missing: cap | Show results with:cap
  105. [105]
    Merck CEO Frazier finds fault in new studies suggesting pharma ...
    Mar 3, 2020 · Merck CEO Kenneth Frazier wrote in a JAMA editorial that comparing pharma companies to the diverse industries represented by the S&P 500 is problematic.
  106. [106]
    Pharma industry is 'right in the crosshairs,' Merck CEO Kenneth ...
    Oct 10, 2019 · Every person running for president has a plan to reduce pharmaceutical pricing,” Merck CEO Kenneth Frazier says.
  107. [107]
    C-Suite Diversity Struggles As Merck's CEO Ken Frazier Is Leaving
    Feb 10, 2021 · The African American Fortune 500 CEO number will now stand at just 4, as Ken Frazier, Merck's MRK-0.5% CEO gets ready to depart, ...
  108. [108]
    Path to the C-suite: Increasing Black Representation at the ... - SHRM
    Only 1 percent of Fortune 500 CEOs are Black. Here's how companies can speed up the pace of change for rising Black executives.Missing: outcomes critiques